Sandra Campos is recorded as CEO at Petmed Express Inc (PETS) since April 29, 2024. Petmed Express Inc reported in an 8-K filed August 12, 2025 that Sandra Campos resigned as director, effective August 11, 2025. Petmed Express Inc reported in an 8-K filed August 12, 2025 that Sandra Campos resigned as Chief Executive Officer (Principal Executive Officer) and President, effective August 11, 2025. Petmed Express Inc reported in an 8-K filed April 29, 2024 that Sandra Campos was appointed President and CEO. Equibles holds 4 filed executive changes naming Sandra Campos; each is listed under recent activity with its source filing. The proxy statement of Petmed Express Inc reports total compensation of $683,759 for Sandra Campos in fiscal 2026, including a base salary of $224,231. Disclosed compensation is on record for 2 fiscal years. Sandra Campos has spoken on 5 earnings calls across 1 company, most recently for Petmed Express Inc on February 10, 2025. Petmed Express Inc is classified in the Pharmaceutical Retailers industry within the Healthcare sector. Other leadership on record at Petmed Express Inc includes Bruce S. Rosenbloom (CEO), Jeff Willard (CEO and Board Member), Jeffrey Allen Willard (CEO and Board Member) and 7 others.
“As a part of Ms. Campos' resignation as an officer of the Company, Ms. Campos also resigned as a director of the Company on and effective as of August 11, 2025.”
Petmed Express Inc Form 8-K, filed August 12, 2025
· Read the filing
“On August 11, 2025, following a meeting of the Board of Directors (the "Board") of PetMed Express, Inc. (the "Company"), the Company and Sandra Campos entered into a Separation Agreement pursuant to which Ms. Campos resigned as the Chief Executive Officer (Principal Executive Officer) and President of the Company, effective immediately (the "Campos Separation Agreement").”
Petmed Express Inc Form 8-K, filed August 12, 2025
· Read the filing
Sandra Campos on recent calls
“Following my remarks, Robyn will provide a detailed overview of our financial results, after which we'll open the lines for your questions. Over the past nine months, I have emphasized that our focus remains steadfast on the strategic initiatives pivotal to repositioning PetMed and PetCareRx for long-term success.”
“Following my remarks, Christine will provide an overview of our financials, after which we will open the lines for your questions. As we close out the first quarter of our fiscal year 2025, it's important to note that Q1 results reflect a transition quarter for the company.”
“It is a true pleasure to speak with all of you for the first time, and let me just start by saying how incredibly honored I am to lead this company at such a pivotal point.”
“It is a true pleasure to speak with all of you for the first time, and let me just start by saying how incredibly honored I am to lead this company at such a pivotal point.”
